Navigation Links
Understanding why C. difficile causes disease -- it's hungry

nd his colleague, Bruno Dupuy from the Institut Pasteur. One codes for a protein, known as R, that is necessary for the expression of the first three genes and the other codes for a protein called C that prevents R from acting.

A mutation in the C protein gene, leaving R unchecked, is the cause of the hypervirulent strain. Sonenshein and his colleagues are currently working to identify a protein that might shut down the gene that codes for R. By identifying such a protein, Sonenshein hope to find a way to change the appetite of the bacteria. "If we find a way to shut down toxin production in the hypervirulent strain, we might have a new way to treat the disease," says Sonenshein.
'"/>

Source:American Society for Microbiology


Page: 1 2

Related biology news :

1. The circadian clock: Understanding natures timepiece
2. Breakthrough System for Understanding Ocean Plant Life Announced
3. Understanding how bacteria communicate may help scientists prevent disease
4. Understanding biases in epidemic models important when making public health predictions
5. Understanding the oceans microbes is key to the Earths future
6. Understanding the actions of others requires the frontal cortex
7. Reminding doctors which antibiotics to prescribe cuts C. difficile infection rates
8. BRCA1 causes ovarian cancer through indirect, biochemical route
9. Researchers discover molecule that causes secondary stroke
10. NASA study finds snow melt causes large ocean plant blooms
11. Alarm pheromone causes aphids to sprout wings
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Understanding why difficile causes disease hungry

(Date:7/9/2015)... 2015  Unchained Labs just can,t get enough ... Avid Nano. Avid Nano designs, develops and manufactures ... Also today, Unchained Labs UNcaged the ... use protein sizing system. The pUNk is a ... size, size distribution, aggregation population and molecular weight. ...
(Date:7/8/2015)... July 8, 2015  Trovagene, Inc. (NASDAQ: ... today announced the launch of a study that ... Cancer Monitoring℠ (PCM) technology for predicting response to ... a combination of the novel immunotherapy agents Yervoy® ... PD-1 inhibitor. The 50-patient study will be led ...
(Date:7/7/2015)... 2015 NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or ... commerce market announces a revised version of one of its first ... air on CNBC in New York , ... San Francisco metro areas.    ... ability to replace all the cards in your wallet and keep ...
Breaking Biology News(10 mins):Unchained Labs just can't get enough, acquires Avid Nano, rocks out the new pUNk! 2Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 2Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 4Wocket Smart Wallet Commercials Airing on CNBC to Showcase This Summer's Must- Have Tech Product 2Wocket Smart Wallet Commercials Airing on CNBC to Showcase This Summer's Must- Have Tech Product 3
... body's natural immune responses could be a target of future cancer ... of Medicine of the University of Southern California. , The ... of Pathology, is the first to identify how EphB4 ?a protein ... important aspect of this study is that ?if we turn the ...
... uncovered a new cellular secret that may explain how ... cancers that makes treatment especially difficult. If the mechanism ... can be understood well enough to manipulate it, new ... metastatic cancers. , Significance of the Mayo Clinic ...
... potentially powerful new therapy for treating diabetes, peripheral vascular ... and into animals by demonstrating it restores nerve and ... particularly important implications for the estimated 21 million Americans ... blood vessels. , The therapy involves netrins, a family ...
Cached Biology News:USC researchers investigate protein that protects tumors 2Mayo Clinic researchers discover cancer cells may move via wave stimulation 2Mayo Clinic researchers discover cancer cells may move via wave stimulation 3Proteins spur diabetic mice models to grow blood vessels, nerves 2
(Date:7/28/2015)... ZIONA, Israel , July ... (TASE:CLPT; OTC:CQPTY), a regenerative medicine company utilizing its ... today announced that Shomrat Shurtz has been appointed ... 2015.      (Photo: http://photos.prnewswire.com/prnh/20150728/246955 ... 25 years of experience in marketing, regulatory and ...
(Date:7/27/2015)... and FRANKLIN, Tenn. ... a privately-owned  premier provider of health care services ... in the U.S., today announced that its parent ... signed a definitive agreement with Medical Properties Trust, ... acquisition of Capella for $900 million in cash.  The transaction ...
(Date:7/27/2015)... ... 2015 , ... Production of high tenacity filament yarn of viscose rayon (excluding ... For instance, it surpassed the EUR 106 million mark (in value terms) in 2013, ... a major producer, while Italy is a key consumer. , The high tenacity ...
(Date:7/27/2015)... Research presented at the 2015 AACC Annual Meeting & ... led to a fingerprick Ebola test becoming the first ... approval from the World Health Organization (WHO). This test ... West Africa by identifying suspected Ebola ... and treat these patients much faster than is currently ...
Breaking Biology Technology:CollPlant Names Shomrat Shurtz Senior Director of Business Development 2Capella Healthcare Announces Agreement With Medical Properties Trust, Inc. 2Capella Healthcare Announces Agreement With Medical Properties Trust, Inc. 3Capella Healthcare Announces Agreement With Medical Properties Trust, Inc. 4Capella Healthcare Announces Agreement With Medical Properties Trust, Inc. 5High Tenacity Filament Yarn of Viscose Rayon Consumption to Grow Swiftly in the EU, Forecasts BAC Reports in New Study Available at MarketPublishers.com 2Rapid Ebola Test Could Play Key Role in Efforts to End Lingering Outbreak 2Rapid Ebola Test Could Play Key Role in Efforts to End Lingering Outbreak 3
... , Revamilast is a PDE4 inhibitor, under development for ... successfully completed pre-clinical trials and Phase I studies , Phase ... UK , , Glenmark has initiated global  Phase IIb ... unmet medical need as globally they are over 300 million Asthma ...
... QinetiQ North America today announced the results of its ... experiment, which studied the effects of microgravity on host ... results of this experiment showed both the plants and ... (Biological Research In a Canister) homes on the shuttle. ...
... Bharat Renewable Energy Ltd (BREL) , a joint-venture of ... a program with SG Biofuels (SGB) to ... production of biodiesel in India. The program,s ... high performing hybrid varieties of Jatropha adapted to unique ...
Cached Biology Technology:Glenmark Initiates Phase IIb Human Trials Globally for its Novel Molecule 'Revamilast' 2Glenmark Initiates Phase IIb Human Trials Globally for its Novel Molecule 'Revamilast' 3Glenmark Initiates Phase IIb Human Trials Globally for its Novel Molecule 'Revamilast' 4QinetiQ North America Gains New Insights into Plant Growth and Sustainable Life Support on Final Shuttle Flight 2Bharat Renewable Energy Forms Alliance With SG Biofuels to Deploy Jatropha Hybrids for Biodiesel in India 2